Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > GUDATE

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Apr 23, 2021 10:17am

119 Views

Post# 33054571

RE:RE:RE:GUDATE

Doccole wrote:
I am just waiting for the LATAM GUD deal. I've been saying this for months.

Mugs how much of the GUD prospectus is left for GUD after this deal?

Shelf prospectus wasn't used - all cash

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale